Please login to the form below

Not currently logged in
Email:
Password:

Boehringer and Zealand focus on diabetes

Zealand Pharma and Boehringer Ingelheim have agreed an exclusive global licence and collaboration agreement for a treatment for patients with type 2 diabetes and obesity

Zealand Pharma and Boehringer Ingelheim have agreed an exclusive global licence and collaboration agreement for dual-acting glucagon and GLP-1 receptor agonists for the treatment of patients with Type-2 diabetes and obesity.

Boehringer Ingelheim will obtain global development and commercialisation rights to ZP2929, Zealand Pharma's lead glucagon/GLP-1 dual agonist drug candidate. Zealand Pharma will be responsible for conducting the first phase I study with ZP2929 and Boehringer Ingelheim will fund the research, development and commercialisation of products under the agreement.

Zealand Pharma will be eligible to receive payments for ZP2929 and could receive additional milestone payments if other products covered by the collaboration are advanced through development. Zealand Pharma is also entitled to tiered royalties that range from high single to low double digits on global sales of products under the agreement. Zealand Pharma retains co-promotion rights in Scandinavia.

During the first two years of collaboration, Zealand Pharma is eligible to receive signature, milestone, and other payments of up to €41m including cost reimbursements and including research funding of up to €4m. 

In their research collaboration, Zealand Pharma and Boehringer Ingelheim will focus on the characterisation, identification and development of additional glucagon/GLP-1 dual agonists for the exploration of new indications, formulations and delivery systems.

Prof Dr Klaus Dugi, Boehringer Ingelheim's corporate senior vice president of medicine, said: "Our focus to develop innovative diabetes treatments is reinforced by the in-licensing of a very interesting compound from Zealand Pharma which complements Boehringer Ingelheim's pipeline in diabetes and metabolic diseases very well. 

"With our first diabetes treatment linagliptin recently approved by the FDA, we have a manifest for Boehringer Ingelheim's own research strength and its capability to bring novel medication to the patients. We are therefore pleased to bundle our R&D experience with Zealand Pharma for further projects in diabetes and obesity," he added.

16th June 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Kendle Healthcare

Company founder Neil Kendle was a pioneer in opinion leader engagement. In 2003, Neil brought together a small, dedicated team...

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...

Infographics